Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the phase 3 trial of ninlaro as first line maintenance therapy in multiple myeloma patients.
Phase 3 Trial of NINLARO (ixazomib) as First Line Maintenance Therapy
